The estimated Net Worth of Rajiv I. Modi is at least $99.6 Million dollars as of 16 June 2015. Rajiv Modi owns over 433,053 units of Novavax stock worth over $30,725,000 and over the last 11 years he sold NVAX stock worth over $68,897,801. In addition, he makes $0 as Director at Novavax.
Rajiv has made over 8 trades of the Novavax stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 433,053 units of NVAX stock worth $3,901,808 on 16 June 2015.
The largest trade he's ever made was selling 3,500,000 units of Novavax stock on 28 May 2015 worth over $30,590,000. On average, Rajiv trades about 1,250,000 units every 58 days since 2014. As of 16 June 2015 he still owns at least 2,500,000 units of Novavax stock.
You can see the complete history of Rajiv Modi stock trades at the bottom of the page.
Dr. Rajiv I. Modi Ph.D. serves as Director of the Company., since April 1, 2009. He is Chairman and Managing Director of Cadila Pharmaceuticals, Ltd. (“Cadila”), a company organized in India, since 1995. Dr. Modi was elected to Novavax, Inc.’s Board based upon his relationship with the Company’s largest stockholder at the time. As of April 29, 2020, Satellite Overseas (Holdings) Limited, a subsidiary of Cadila, holds less than one percent of the Company’s outstanding Common Stock. Dr. Modi serves as a member of the boards of other Cadila group companies. Dr. Modi serves as a member of the board of Cadila, as well as the boards of numerous other private companies and foreign public companies. Dr. Modi received a bachelor’s degree of technology in chemical engineering from the Indian Institute of Technology, a master’s degree in biological engineering from University College, London, and a Ph.D. in biological science from the University of Michigan.
Rajiv Modi is 59, he's been the Director of Novavax since 2009. There are 13 older and 9 younger executives at Novavax. The oldest executive at Novavax, Inc. is Michael McManus, 77, who is the Independent Director.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi, and Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: